May 23, 2017 | 11 am to 12 pm EDT

Sponsored by

Webinar Description:

The emergence of fragment-based approaches was heralded as one of the most exciting recent developments in early stage drug discovery. But 10 years on, what have we learnt and how do you harness this knowledge to optimise the search for your next drug candidate?

This webinar will look back on 10 years of fragment based drug discovery, to distill and discuss the key requirements for a successful hit discovery programme. It will cover the range of orthogonal screening techniques available, including the pros and cons of each, and how to decide which is best for you. It will also include real fragment based case studies including the identification and development of Domainex’s own drug candidate, DMXD-011 (a TBK1/IKKƐ inhibitor) and recent work to identify lysine methyltransferase inhibitors.

Learning Objectives:

• Gain an overview, and understand key developments, of fragment based research
• Learn about the merits of the range of orthogonal assays used in fragment based screening
• An insight to the suitability of fragment based drug design for your discovery programme

Speaker Information:

Trevor Perrior, Ph.D.

Chief Scientific Officer

Domainex

Professor Perrior has led numerous drug discovery teams and successfully delivered development candidates across several therapeutic areas. Educated at the University of Cambridge, Trevor undertook academic research at Cambridge, Oxford and in the USA. He then held a number of senior R&D roles in the pharmaceutical and biotechnology companies ICI, Zeneca, AstraZeneca and Celltech, where he worked on sites in the UK, USA, and Switzerland.

In 2005, he became Chief Scientific Officer at NCE Discovery which went on to merge with Domainex. Trevor is also a scientific consultant to a number of venture capital and charitable funds, and is the Visiting Professor of Medicinal Chemistry at University of Sussex, where he chairs the Translational Drug Discovery Steering Committee.